Aging eyes linked to sleepless nights, new study shows

Cataract could be factor in frequent insomnia among elderly

 

Darien, Illinois, USA (September 1, 2011) – A natural yellowing of the eye lens that absorbs blue light has been linked to sleep disorders in a group of test volunteers, according to a study in the September 1 issue of the journal Sleep. As this type of lens discoloration worsened with age, so did the risk of insomnia.

 

"The strong link between lens yellowing and age could help explain why sleep disorders become more frequent with increasing age," said Line Kessel, M.D., Ph.D., the study’s lead author.

 

In the Danish study, 970 volunteers had their eyes examined by lens autofluorometry, a non-invasive method for determining how much blue light is transmitted into the retina. Blue light is a portion of the visible-light spectrum that influences the normal sleep cycle by helping initiate the release of melatonin in the brain. Melatonin is a hormone that helps signal to the body when it is time to be sleepy or alert.

 

Volunteers were considered to have a sleep disorder if they confirmed that they "often suffer from insomnia" or if they purchased prescription sleeping pills within the last 12 months. Of those classified as having a sleep disturbance, 82.8 percent affirmed that they both suffered from insomnia and used sleep medication.

 

Using this data, researchers calculated an inverse relationship between blue light transmission and the risk of having sleep disturbances: the lower the blue light transmission into the retina due to a yellowing of the eye lens, the greater the risk of sleep disturbances.

 

"The results showed that while age-related lens yellowing is of relatively little importance for visual function, it may be responsible for insomnia in the elderly," said Kessel, a senior scientist in the Department of Opthalmology at Glostrup Hospital in Denmark.

 

Significantly higher rates of sleep disorders were reported by older participants, women, smokers and those with diabetes mellitus. Previous studies have shown that the rate of lens aging is accelerated in smokers, patients with diabetes mellitus and those at high risk for ischemic heart diseases. The Danish researchers addressed these factors in their statistical analyses.

 

"The association between blue light lens transmission and sleep disturbances remained significant even after we corrected for age, sex, diabetes mellitus, smoking and the risk of ischemic heart disease," Kessel said.

 

She said another important factor to consider is that sleep quality has been shown to improve after cataract surgery. "The transmission of blue light currently cannot be improved by any other method than cataract surgery. I´m involved with another research project where we try non-invasively to remove the yellow color of the lens using a laser, but the method is not yet developed for clinical use," Kessel said.

 

In the meantime, Kessel said it seemed prudent to recommend that physicians reconsider the prescription of sleeping tablets in patients who have undergone cataract surgery.

 

 

This study was sponsored, in part, by The Danish Pharmaceutical Association and the healthcare company Novo Nordisk, which specializes in diabetes care.

 

Read more about sleep and older adults from the American Academy of Sleep Medicine on the Sleep Education Blog at http://sleepeducation.blogspot.com/search/label/older%20adults

 

The monthly, peer-reviewed, scientific journal Sleep is published online by the Associated Professional Sleep Societies LLC, a joint venture of the American Academy of Sleep Medicine and the Sleep Research Society. The AASM is a professional membership society that is the leader in setting standards and promoting excellence in sleep medicine health care, education and research (www.aasmnet.org)

 


 

American Academy of Sleep Medicine, 01.09.2011 (tB).

MEDICAL NEWS

COVID-19 vaccines are estimated to have prevanented 20 million deaths…
Novel sleep education learning modules developed for nurse practitioners
Inadequate sequencing of SARS-CoV-2 variants impedes global response to COVID-19
New meta-analysis finds cannabis may be linked to development of…
New guidance on how to diagnosis and manage osteoporosis in…

SCHMERZ PAINCARE

Aktuelle Versorgungssituation der Opioidtherapie im Fokus
Individuelle Schmerztherapie mit Opioiden: Patienten im Mittelpunkt
Versorgung verbessern: Deutsche Gesellschaft für Schmerzmedizin fordert die Einführung des…
Pflegeexpertise im Fokus: Schmerzmanagement nach Operationen
Versorgung verbessern: Bundesweite Initiative der Deutschen Gesellschaft für Schmerzmedizin zu…

DIABETES

Typ-1-Diabetes: InRange – auf die Zeit im Zielbereich kommt es…
Suliqua®: In komplexem Umfeld – einfach besser eingestellt
Suliqua®: Überlegene HbA1c-Senkung  im Vergleich zu Mischinsulinanalogon
„Wissen was bei Diabetes zählt: Gesünder unter 7 PLUS“ gibt…
Toujeo® bei Typ-1-Diabetes: Weniger schwere Hypoglykämien und weniger Ketoazidosen 

ERNÄHRUNG

Mangelernährung gefährdet den Behandlungserfolg — DGEM: Ernährungsscreening sollte zur klinischen…
Wie eine Diät die Darmflora beeinflusst: Krankenhauskeim spielt wichtige Rolle…
DGEM plädiert für Screening und frühzeitige Aufbautherapie: Stationäre COVID-19-Patienten oft…
Führt eine vegane Ernährungsweise zu einer geringeren Knochengesundheit?
Regelmässiger Koffeinkonsum verändert Hirnstrukturen

ONKOLOGIE

Krebspatienten unter Immuntherapie: Kein Hinweis auf erhöhtes Risiko für schwere…
WHO veröffentlicht erste Klassifikation von Tumoren im Kindesalter
Anti-Myelom-Therapie mit zusätzlich Daratumumab noch effektiver
Positive Ergebnisse beim fortgeschrittenen Prostatakarzinom: Phase-III-Studie zur Radioligandentherapie mit 177Lu-PSMA-617
Lymphom-News vom EHA2021 Virtual. Alle Berichte sind nun online verfügbar!

MULTIPLE SKLEROSE

Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?
Neuer Therapieansatz für Multiple Sklerose und Alzheimer
„Ich messe meine Multiple Sklerose selbst!“ – Digitales Selbstmonitoring der…
Stellungnahme zur 3. Impfung gegen SARS-CoV2 bei Personen mit MS
NMOSD-Erkrankungen: Zulassung von Satralizumab zur Behandlung von Jugendlichen und Erwachsenen

PARKINSON

Alexa, bekomme ich Parkinson?
Meilenstein in der Parkinson-Frühdiagnose
Parkinson-Erkrankte besonders stark von Covid-19 betroffen
Gangstörungen durch Kleinhirnschädigung beim atypischen Parkinson-Syndrom
Parkinson-Agenda 2030: Die kommenden 10 Jahre sind für die therapeutische…